Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase

Nucleosides and Nucleotides

Volumn 18, Issue 4-5, 1999, Pages 745-757

  Secrist III, John A ^a   Parker, William B ^a   Allan, Paula W ^a   Bennett Jr , L Lee ^a   Waud, William R ^a   Truss, Jackie W ^a   Fowler, Anita T ^a   Montgomery, John A ^a   Ealick, Steven E ^b   Wells, Alan H ^c   Gillespie, G Yancey ^c   Gadi, V K ^c   Sorscher, Eric J ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; NUCLEOSIDE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; VIRUS VECTOR;

CANCER THERAPY; CONFERENCE PAPER; CYTOTOXICITY; DRUG ACTIVATION; DRUG SELECTIVITY; GENE TARGETING; GENE THERAPY;

HERPES; SIMPLEXVIRUS;

EID: 0033027043     PISSN: 07328311     EISSN: None     Source Type: Journal    
DOI: 10.1080/15257779908041562     Document Type: Conference Paper

References (18)

1. Sorscher, E.J.; Peng, S.; Bebok, Z.; Allan, P.A.; Bennett, L.L. Jr.; Parker, W.B. Tumor Cell Bystander Killing in Colonic Carcinoma Utilizing the Escherichia Coli DeoD Gene to Generate Toxic Purines. Gene Therapy, 1994, 1, 233-238.
2. Hughes, B.W.; Wells, A.H.; Bebok, Z.; Gadi, V.K.; Garver, R.I. Jr.; Parker, W.B.; Sorscher, E.J. Bystander Killing of Melanoma Cells Using the Human Tyrosinase Promoter to Express the Escherichia coli Purine Nucleoside Phosphorylase Gene. Cancer Res., 1995, 55, 3339-3345.
3. Parker, W.B.; King, S.A.; Allan, P.W.; Bennett, L.L. Jr.; Secrist, J.A. III; Montgomery, J.A.; Gilbert, K.S.; Waud, W.R.; Wells, A.H.; Gillespie, G.Y.; Sorscher, E.J. In Vivo Gene Therapy of Cancer with E. coli Purine Nucleoside Phosphorylase. Hum. Gene Ther., 1997, 8, 1637-1644.
4. Mao, C.; Cook, W.J.; Zhou, M.; Koszalka, G.W.; Krenitsky, T.A.; Ealick, S.E. The Crystal Structure of Escherichia coli Purine Nucleoside Phosphorylase: A Comparison with the Human Enzyme Reveals a Conserved Topology. Structure, 1997, 5, 1373-1383.
5. Parker, W.B.; Allan, P.W.; Shaddix, S.C.; Rose, L.M.; Speegle, H.F.; Gillespie, G.Y.; Bennett, L.L. Jr. Metabolism and Metabolic Actions of 6-Methylpurine and 2-Fluoroadenine in Human Cells. Biochem. Pharmacol., 1998, 55, 1673-1681.
6. Hughes, B.W.; King, S.A.; Allan, P.W.; Parker, W.B.; Sorscher, E.J. Cell to Cell Contact Is Not Required for Bystander Cell Killing by Escherichia coli Purine Nucleoside Phosphorylase. J. Biol. Chem., 1998, 273, 2322-2328.
7. McNeish, I.A.; Searle, P.F.; Young, L.S.; Kerr, D.J. Gene Directed Enzyme Prodrug Therapy for Cancer. Adv. Drug Del. Rev., 1997, 26, 173-184.
8. Niculescu-Duvaz, I.; Spooner, R.; Marais, R.; Springer, C.J. Gene-Directed Enzyme Prodrug Therapy. Bioconjugate Chem., 1998, 9, 4-22.
9. Doskočil, J.; Holý, A. Specificity of Purine Nucleoside Phosphorylase From Escherichia coli. Coll. Czech. Chem. Commun.., 1977, 42, 370-383.
10. Zintchenko, A.I.; Eroshevskaya, L.A.; Barai, V.N.; Mikhailopulo, I.A. Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia coli. Nucleic Acids Res., 1987, 18, 137-140.
11. Bzowska, A.; Kulikowska, E.; Shugar, D. Properties of Purine Nucleoside Phosphorylase (PNP) of Mammalian and Bacterial Origin. Z. Naturforsch., 1990, 45c, 59-70.
12. Bzowska, A.; Kulikowska, E.; Shugar, D. Formycins A and B and Some Analogues: Selective Inhibitors of Bacterial (Escherichia coli) Purine Nucleoside Phosphorylase. Biochim. Biophys. Acta, 1992, 1120, 239-247.
13. Bzowska, A.; Ananiev, A.V.; Ramzaeva, N.; Alksins, E.; Maurins, J.A.; Kulikowska, E.; Shugar, D. Purine Nucleoside Phosphorylase: Inhibition by Purine N(7)- and N(9)-Acyclonucleosides; and Substrate Properties of 7-β-D-Ribofuranosylguanine and 7-β-D-Ribofuranosylhyposanthine. Biochem. Pharmacol., 1994, 48, 937-947.
14. Wierzchowski, J.; Wielgus-Kutrowska, B.; Shugar, D. Fluorescence Emission Properties of 8-Azapurines and Their Nucleosides, and Application to the Kinetics of the Reverse Synthetic Reaction of Purine Nucleoside Phosphorylase. Biochim.Biophys. Acta, 1995, 1290, 9-17.
15. Bzowska, A.; Kulikowska, E.; Poopeiko, N.E.; Shugar, D. Kinetics of Phosphorolysis of 3-(β-D-Ribofuranosyl)adenine and 3-(β-D-Ribofuranosyl)hypoxanthine, Non-conventional Substrates of Purine-Nucleoside Phosphorylase. Eur. J. Biochem., 1996, 239, 229-234.
16. Wielgus-Kutrowska, B.; Kulikowska, E.; Wierzchowski, J.; Bzowska, A.; Shugar, D. Nicotinamide Riboside, An Unusual, Non-Typical, Substrate of Purified Purine-Nucleoside Phosphorylases. Eur. J. Biochem., 1997, 243, 408-414.
17. Leopold, W.R.; Fry, D.W.; Boritzki, T.J.; Besserer, J.A.; Pattison, I.C.; Jackson, R.C. Dezaguanine Mesylate: A New Antipurine Antimetabolite. Invest. New Drugs, 1985, 3, 223-231.
18. Bennett, L.L. Jr.; Smithers, D.; Rose, L.M.; Adamson, D.J.; Brockman, R.W. Mode of Action of 2-Amino-6-Chloro-1-Deazapurine. Biochem. Pharmacol., 1984, 33, 261-271.